Drug Trial Radar · NCT05297448
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
517
Actual
Start
Aug 3, 2022
Primary completion
Feb 24, 2026
Study completion Feb 24, 2026
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
Conditions
- Hepatic Encephalopathy
Interventions
Rifaximin SSDDrug
Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
PlaceboDrug
Placebo Twice Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Event of Overt Hepatic Encephalopathy (OHE) Requiring Medical Intervention in the Hospital/Emergency Room (ER)/Emergency Department (ED)/Clinic or DeathTime frame: 72-week trial drug administration period.
Locations
188 sites in 17 countries. Site status is shown where the registry gives one.
Bausch Site 591
Homewood, Alabama
Bausch Site 445
Chandler, Arizona
Bausch Site 453
Sun City, Arizona
Bausch Site 587
Tucson, Arizona
Bausch Site 550
Bakersfield, California
Bausch Site 415
Coronado, California
Bausch Site 585
Covina, California
Bausch Site 585
Covina, California
Bausch Site 592
Fresno, California
Bausch Site 582
Lancaster, California
Bausch Site 590
Long Beach, California
Bausch Site 414
Los Angelesq, California
Bausch Site 405
Orange, California
Bausch Site 482
Valencia, California
Bausch Site 575
Colorado Springs, Colorado
Bausch Site 425
Doral, Florida
Bausch Site 449
Hialeah, Florida
Bausch Site 558
Hialeah, Florida
Bausch Site 418
Hialeah, Florida
Bausch Site 468
Hollywood, Florida
Bausch Site 495
Miami, Florida
Bausch Site 543
Miami, Florida
Bausch Site 479
Miami, Florida
Bausch Site 428
Miami, Florida
Bausch Site 470
Miami, Florida
Bausch Site 486
Miami, Florida
Bausch Site 552
Miami, Florida
Bausch Site 594
Miami, Florida
Bausch Site 456
Miami, Florida
Bausch Site 458
Miami, Florida
Bausch Site 435
Miami, Florida
Bausch Site 452
Miami Lakes, Florida
Bausch Site 431/443
Ocala, Florida
Bausch Site 450
Ocala, Florida
Bausch Site 446
Ocoee, Florida
Bausch Site 421
Orange City, Florida
Bausch Site 596
Orlando, Florida
Bausch Site 537
Palmetto Bay, Florida
Bausch Site 407
Port Orange, Florida
Bausch Site 454
Wellington, Florida
Showing 40 of 188 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.